Wednesday, October 16, 2019 10:03:24 AM
Recent AQST News
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 10/02/2024 06:16:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 12:46:44 PM
- Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day • GlobeNewswire Inc. • 09/27/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 12:56:17 PM
- Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th • GlobeNewswire Inc. • 09/09/2024 12:15:00 PM
- Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 08/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:08:37 PM
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™ • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 06:45:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:26:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:24:46 PM
- Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 08:22:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 12:16:24 PM
- Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study • GlobeNewswire Inc. • 07/25/2024 12:00:00 PM
- Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET • GlobeNewswire Inc. • 07/23/2024 12:00:00 PM
- Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024 • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 04:36:13 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 04:35:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 12:13:32 PM
FEATURED Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • CBDL • Oct 8, 2024 8:00 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM